What are 5 of the issues that may need to be addressed in the decision-making process when choosing a lead compound?在选择先导化合物时，决策过程中可能需要解决的五个问题有哪些？

Question

BlackTom AI · Accepted Answer

Potency and biological activity are primary considerations: a lead must show sufficient effect on the biological target (low IC50/EC50) in relevant assays.

1) Relevant knowledge points and concepts
- Potency/biological activity: measured by IC50, EC50, Ki; determines whether the compound produces the desired pharmacological effect at achievable concentrations.
- Selectivity: the compound should preferentially modulate the intended target versus off‑targets to reduce side effects (selectivity ratio, fold‑selectivity).
- ADME (Absorption, Distribution, Metabolism, Excretion): properties such as solubility, permeability, metabolic stability, plasma protein binding, and clearance govern exposure and dosing.
- Toxicity/safety: acute and chronic toxicity, cytotoxicity, cardiodisposition liabilities (e.g., hERG), genotoxicity and safety margins (therapeutic index).
- Synthetic accessibility / ease of optimization: the practicality of making analogues (scalability, number of synthetic steps, availability of building blocks) affects lead optimisation speed and cost.

2) Step‑by‑step reasoning process
- Start by ranking hits by potency: compare IC50 values (e.g., 10 nM = 0.01 μM vs 1 μM; the 10 nM compound is 100× more potent).
- Check selectivity: calculate fold‑selectivity against related targets; deprioritise compounds with poor selectivity even if potent.
- Evaluate ADME data: poor solubility or high clearance can make a potent compound useless in vivo. For example, intrinsic clearance values guide expected in vivo half‑life.
- Assess early safety flags: cytotoxicity or hERG activity reduces the likelihood of success and increases attrition risk.
- Review synthetic tractability: complex or low‑yield syntheses hinder rapid SAR (structure–activity relationship) exploration and scale‑up.

3) Example calculation (unit conversion to compare potency)
- Compound X IC50 = 10 nM = 0.01 μM. Compound Y IC50 = 1 μM. Potency fold difference = 1 μM / 0.01 μM = 100×. This quantifies why potency is prioritized.

4) Why the correct answer is correct
These five issues directly determine whether a molecule can become a developable drug: biological effect, target specificity, exposure in the body, safety margin, and the ability to chemically optimise and manufacture the molecule.

5) Other considerations (why they are not listed as the five core issues)
Items such as intellectual property, formulation strategy, commercial viability, and target validation are also important but are secondary or downstream to the core physicochemical/biological and synthetic criteria listed above.

Conclusion: The five issues—1) potency/biological activity, 2) selectivity, 3) ADME properties, 4) toxicity/safety, and 5) synthetic accessibility/ ease of chemical modification—match and are confirmed as the correct answer.

What are 5 of the issues that may need to be addressed in the decision-making process when choosing a lead compound?在选择先导化合物时，决策过程中可能需要解决的五个问题有哪些？简答题

类似问题

Library design in PDD;

Which statement best describes a lead-like library?

A 'high-quality' lead compound has the following desirable qualities

A 'high-quality' lead compound has the following desirable qualities

Lead compounds can only come from natural sources

Lipinski's rule of 5 (Ro5) is applicable to the development of: Select all correct answers.

Lead compounds for new drugs can only be synthesized.

Which stages commonly include evaluation of compound safety? (Select all that apply)

更多留学生实用工具

智能学习助手

风格化写作助手

论文查重助手

文献引用助手

课堂转译助手

课堂笔记助手

Quiz搜索助手

学校历年真题

智能刷题助手

智能匹配练习

希望你的学习变得更简单